These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35980472)

  • 1. Molecular assays for determining sulphadoxine-pyrimethamine drug resistance in India: a systematic review.
    Bhullar S; Mishra N
    Parasitol Res; 2022 Oct; 121(10):2765-2774. PubMed ID: 35980472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
    Mohapatra PK; Sarma DK; Prakash A; Bora K; Ahmed MA; Sarma B; Goswami BK; Bhattacharyya DR; Mahanta J
    PLoS One; 2014; 9(9):e105562. PubMed ID: 25184337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania.
    Mbugi EV; Mutayoba BM; Malisa AL; Balthazary ST; Nyambo TB; Mshinda H
    Malar J; 2006 Oct; 5():94. PubMed ID: 17076899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Prevalence of Molecular Markers of Plasmodium falciparum Resistance to Sulphadoxine-Pyrimethamine in Parts of Ghana: A Threat to ITPTp-SP?
    Afutu LL; Boampong JN; Quashie NB
    J Trop Pediatr; 2021 Jan; 67(1):. PubMed ID: 33404643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.
    Mishra S; Bharti PK; Shukla MM; Ali NA; Kashyotia SS; Kumar A; Dhariwal AC; Singh N
    Pathog Glob Health; 2017 Jun; 111(4):186-194. PubMed ID: 28549390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms associated with sulphadoxine-pyrimethamine drug resistance among Plasmodium falciparum field isolates in malaria endemic areas of Assam.
    Sharma J; Dutta P; Khan SA; Soni M; Dey D; Mahanta J
    J Postgrad Med; 2015; 61(1):9-14. PubMed ID: 25511211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana.
    Duah NO; Quashie NB; Abuaku BK; Sebeny PJ; Kronmann KC; Koram KA
    Am J Trop Med Hyg; 2012 Dec; 87(6):996-1003. PubMed ID: 23045251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya.
    Iriemenam NC; Shah M; Gatei W; van Eijk AM; Ayisi J; Kariuki S; Vanden Eng J; Owino SO; Lal AA; Omosun YO; Otieno K; Desai M; ter Kuile FO; Nahlen B; Moore J; Hamel MJ; Ouma P; Slutsker L; Shi YP
    Malar J; 2012 Jul; 11():134. PubMed ID: 22540158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
    Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
    Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology.
    Ballif M; Hii J; Marfurt J; Crameri A; Fafale A; Felger I; Beck HP; Genton B
    Malar J; 2010 Oct; 9():270. PubMed ID: 20925934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.
    Tekete M; Djimde AA; Beavogui AH; Maiga H; Sagara I; Fofana B; Ouologuem D; Dama S; Kone A; Dembele D; Wele M; Dicko A; Doumbo OK
    Malar J; 2009 Feb; 8():34. PubMed ID: 19245687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Plasmodium falciparum Molecular Markers of Antimalarial Drug Resistance in a Residual Malaria Focus Area in Sabah, Malaysia.
    Norahmad NA; Mohd Abd Razak MR; Abdullah NR; Sastu UR; Imwong M; Muniandy PK; Saat MN; Muhammad A; Jelip J; Tikuson M; Yusof N; Rundi C; Mudin RN; Syed Mohamed AF
    PLoS One; 2016; 11(10):e0165515. PubMed ID: 27788228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.
    Malisa AL; Pearce RJ; Abdulla S; Mshinda H; Kachur PS; Bloland P; Roper C
    Malar J; 2010 Jul; 9():190. PubMed ID: 20602754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
    Kinzer MH; Chand K; Basri H; Lederman ER; Susanti AI; Elyazar I; Taleo G; Rogers WO; Bangs MJ; Maguire JD
    Malar J; 2010 Apr; 9():89. PubMed ID: 20370920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of pfdhfr and pfdhps mutations in Plasmodium falciparum associated with drug resistance among pregnant women receiving IPTp-SP at Msambweni County Referral Hospital, Kwale County, Kenya.
    Gikunju SW; Agola EL; Ondondo RO; Kinyua J; Kimani F; LaBeaud AD; Malhotra I; King C; Thiong'o K; Mutuku F
    Malar J; 2020 May; 19(1):190. PubMed ID: 32448228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
    Plowe CV; Cortese JF; Djimde A; Nwanyanwu OC; Watkins WM; Winstanley PA; Estrada-Franco JG; Mollinedo RE; Avila JC; Cespedes JL; Carter D; Doumbo OK
    J Infect Dis; 1997 Dec; 176(6):1590-6. PubMed ID: 9395372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania.
    Matondo SI; Temba GS; Kavishe AA; Kauki JS; Kalinga A; van Zwetselaar M; Reyburn H; Kavishe RA
    Malar J; 2014 Apr; 13():152. PubMed ID: 24751352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India.
    Srivastava P; Ratha J; Shah NK; Mishra N; Anvikar AR; Sharma SK; Das MK; Srivastava B; Valecha N
    Malar J; 2013 Jul; 12():247. PubMed ID: 23866298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran.
    Rouhani M; Zakeri S; Pirahmadi S; Raeisi A; Djadid ND
    Infect Genet Evol; 2015 Apr; 31():183-9. PubMed ID: 25653131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
    Koukouikila-Koussounda F; Bakoua D; Fesser A; Nkombo M; Vouvoungui C; Ntoumi F
    Infect Genet Evol; 2015 Jul; 33():32-6. PubMed ID: 25934142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.